Abstract
Acute myeloid leukemia (AML) with mutated nucleophosmin (NPM1) is a distinct entity often associated with extramedullary involvement. This study investigates whether Epithelial-Mesenchymal Transition (EMT)-related programs contribute to cell invasion in this subtype. By analyzing three patient datasets, researchers identified versican (VCAN) as a key upregulated EMT-related gene. Mechanistic studies showed that NPM1 mutations drive VCAN expression via a TGF-β/cPML/Smad signaling axis. Functional assays demonstrated that VCAN promotes cell migration and invasion, and its high expression correlates with poor prognosis and skin infiltration in AML patients.
Introduction
Acute Myeloid Leukemia (AML) with NPM1 mutations is a distinct clinical entity frequently associated with extramedullary involvement (EMI), where leukemia cells invade tissues outside the bone marrow. While Epithelial-Mesenchymal Transition (EMT) is a well-known driver of metastasis in solid tumors, its role in "liquid" tumors like AML has remained less clear. This study explores whether EMT-related genetic programs are hijacked to facilitate the invasive behavior observed in NPM1-mutated AML.
Identification of VCAN as a Key Driver
The researchers conducted a comprehensive bioinformatics screen using three independent patient datasets (TCGA, GSE34860, and GSE6891) to identify genes specifically upregulated in NPM1-mutated AML.
As illustrated in Figure 4A-C, the intersection of these datasets revealed 544 consistently upregulated genes. Cross-referencing these with a panel of 84 key EMT-related genes identified VCAN (Versican) and DSC2 as the primary candidates. Validation across various AML cell lines (Figure 4D) confirmed that VCAN expression is significantly higher in the NPM1-mutated OCI-AML3 line compared to wild-type controls.
Mechanistic Pathway: TGF-β/cPML/Smad
The study elucidated a novel signaling axis driving VCAN expression. The NPM1 mutation causes the PML protein to localize in the cytoplasm (cPML), where it acts as a scaffold to amplify TGF-β signaling. This activation leads to increased Smad phosphorylation and subsequent transcriptional up-regulation of VCAN.
The researchers confirmed this mechanism using targeted inhibitors:
- LY364947 (TGF-β inhibitor) and Leptomycin B (inhibitor of cPML formation) both effectively suppressed VCAN levels in NPM1-mutated cells.
Functional Impact and Clinical Relevance
Functional assays demonstrated that silencing VCAN via shRNA significantly impaired the ability of OCI-AML3 cells to migrate and invade through Matrigel. Conversely, inducing the NPM1 mutation in wild-type cells boosted VCAN expression and enhanced invasive potential.
The clinical significance of these findings is profound. Analysis of patient data showed that high VCAN expression correlates with a higher percentage of leukemia cells in the skin (Figure 4E), providing a molecular basis for leukemia cutis. Furthermore, patients with high VCAN expression faced a significantly poorer prognosis, with a median survival of 12.17 months versus 26.40 months for those with low expression (p = 0.0247).
Conclusion
This research identifies VCAN as a critical mediator of tissue invasion in NPM1-mutated AML, driven by a hijacked EMT-like program via the TGF-β/cPML signaling axis. These insights position VCAN as a valuable prognostic biomarker and a potential therapeutic target to prevent extramedullary spread in aggressive leukemia.
Summary updated